In conclusion, we believe that more high-quality, large sample, multicenter, fully randomized, double-blind controlled clinical trials are needed to demonstrate whether erythropoietin has an effect on the survival of lung cancer patients, so as to obtain more valuable meta-analysis results. Here, EPO is linked to lung carcinoma.